0QV2 Stock Chart & Stats
kr16.20
kr12.00(19.35%)
At close: 4:00 PM EST
kr16.20
kr12.00(19.35%)
Day’s Range― - ―
52-Week Rangekr15.00 - kr74.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
kr539.68M
Enterprise Valuekr667.26M
Total Cash (Recent Filing)kr43.52M
Total Debt (Recent Filing)kr157.09M
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Oct 22, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend Yield0.25%
Share Statistics
EPS (TTM)-0.24
Shares Outstanding31,043,884
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.22
Price to Book (P/B)2.21
Price to Sales (P/S)3.23
P/FCF Ratio-96.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.25
Revenue Forecast (FY)kr214.24M
Bulls Say, Bears Say
Bulls Say
Operational RecoveryThe return to positive EBITDA and operating cash generation indicates that cost structure and operational execution have improved materially from earlier losses. If maintained, this recovery can support reinvestment, strengthen resilience, and provide a foundation for eventual bottom-line profitability.
Manageable LeverageModerate and stable leverage gives Bactiguard more financial flexibility than a heavily indebted business would have. Limited debt growth can reduce balance-sheet pressure, preserve capacity to fund product and partnership development, and improve the company’s ability to absorb operating volatility.
Scalable Licensing ModelLicensing BIP to medical-device manufacturers can expand market reach without relying solely on Bactiguard’s own distribution footprint. Broader adoption across partner products could create volume-linked income and diversify revenue beyond direct sales of coated devices.
Bears Say
Unprofitable OperationsDespite improved EBITDA, the company still has not converted operating progress into positive EBIT, net income, or returns on equity. Continued losses weaken internal capital accumulation and indicate that Bactiguard’s current revenue base and cost structure remain insufficient for durable shareholder value creation.
Gross Margin PressureA sustained reduction in gross margin would limit the earnings benefit of revenue growth and make profitability more dependent on further cost control. The deterioration also raises unresolved concerns around product mix, pricing, or one-off effects that could constrain margin recovery over coming quarters.
Volatile Cash ConversionPositive TTM cash generation is encouraging, but the sharp swing from negative 2025 cash flow shows that conversion is not yet dependable. Volatility can complicate investment planning, reduce confidence in funding growth internally, and leave results sensitive to working-capital or operating fluctuations.
Bactiguard Holding AB News
0QV2 FAQ
What was Bactiguard Holding AB’s price range in the past 12 months?
Bactiguard Holding AB lowest share price was kr15.00 and its highest was kr74.00 in the past 12 months.
What is Bactiguard Holding AB’s market cap?
Bactiguard Holding AB’s market cap is kr539.68M.
When is Bactiguard Holding AB’s upcoming earnings report date?
Bactiguard Holding AB’s upcoming earnings report date is Oct 22, 2026 which is in 16 days.
How were Bactiguard Holding AB’s earnings last quarter?
Bactiguard Holding AB released its earnings results on Jul 14, 2026. The company reported -kr0.2 earnings per share for the quarter, beating the consensus estimate of -kr0.3 by kr0.1.
Is Bactiguard Holding AB overvalued?
According to Wall Street analysts Bactiguard Holding AB’s price is currently Overvalued.
Does Bactiguard Holding AB pay dividends?
Bactiguard Holding AB pays a Notavailable dividend of kr0.285 which represents an annual dividend yield of 0.25%. See more information on Bactiguard Holding AB dividends here
What is Bactiguard Holding AB’s EPS estimate?
Bactiguard Holding AB’s EPS estimate is -0.2.
How many shares outstanding does Bactiguard Holding AB have?
Bactiguard Holding AB has 31,043,884 shares outstanding.
What happened to Bactiguard Holding AB’s price movement after its last earnings report?
Bactiguard Holding AB reported an EPS of -kr0.2 in its last earnings report, beating expectations of -kr0.3. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Bactiguard Holding AB?
Currently, no hedge funds are holding shares in GB:0QV2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bactiguard Holding AB
Bactiguard Holding AB (publ), a Swedish-based global medical technology company, specializes in developing and supplying innovative solutions designed to prevent infections. Its primary objective is to mitigate healthcare-associated infections (HAIs) and reduce the global dependency on antibiotics. The core of Bactiguard's product line, known as Bactiguard Infection Protection (BIP), encompasses a range of coated medical devices. This includes various urinary catheters, such as the BIP Foley Catheter and the temperature-sensing BIP Foley TempSensor, all engineered to inhibit microbial adhesion and prevent urinary tract infections. Similarly, the BIP Central Venous Catheter and BIP Endotracheal Tube (with the BIP Endotracheal Tube Evac variant offering subglottic secretion drainage) work to reduce the risk of bloodstream and respiratory tract infections by minimizing biofilm formation. Beyond its BIP portfolio, the company offers a diverse array of other products, including Hydrocyn aqua advanced wound care for cleaning and debriding acute, chronic, and infected wounds, as well as general Bactiguard Wound Care items. It also provides a comprehensive selection of surgical sutures (natural absorbable, synthetic absorbable, non-absorbable, and specialty types), VigiMesh for hernia repair, and Hydrocyn aqua advanced disinfectant for sanitizing skin and surfaces. Additionally, Bactiguard supplies specialized orthopedic trauma implants featuring infection prevention technology under the ZNN Bactiguard brand, and the Aniocyn line of wound and skin care products for various pets. Bactiguard Holding AB (publ) was established in 2005 and maintains its headquarters in Tullinge, Sweden.